SCHEMBL25614308

SCHEMBL25614308

C[Si](C)(C)C#Cc1cncc(N2CCC(F)(F)C2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 3/20 0.32
CYP11B2 P19099 3/20 0.32
KCNJ1 P48048 1/20 0.32
KCNH2 Q12809 1/20 0.32
KEAP1 Q14145 1/20 0.31
NFE2L2 Q16236 1/20 0.31
CNR2 P34972 3/20 0.31
ADK P55263 1/20 0.31
CACNA2D1 P54289 1/20 0.31
CACNA2D2 Q9NY47 1/20 0.31
CCR6 P51684 1/20 0.31
LRRK2 Q5S007 1/20 0.31
CHRNB2 P17787 2/20 0.30
CHRNB4 P30926 2/20 0.30
CHRNA3 P32297 2/20 0.30
CHRNA4 P43681 2/20 0.30
GRM5 P41594 1/20 0.30
CLK2 P49760 1/20 0.30
DYRK1A Q13627 1/20 0.30
MAP3K12 Q12852 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25614298 0.81 CHRNB2 (0.40) CYP11B1CYP11B2CHRNB2CHRNB4CHRNA3
SCHEMBL29176234 0.79 CHRNB2 (0.40) ADKCHRNB2CHRNA4
SCHEMBL30811810 0.79 CHRNB2 (0.40) ADKCHRNB2CHRNA4
SCHEMBL29107985 0.79 CHRNB2 (0.40) ADKCHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL29108017 0.77 CHRNB2 (0.39) ADKCHRNB2CHRNA4
SCHEMBL14299569 0.76 ADK (0.47) CYP11B1CYP11B2ADKCCR6LRRK2
SCHEMBL14299573 0.76 CHEK1 (0.40) CYP11B2ADK
SCHEMBL30811822 0.76 CHRNB2 (0.37) ADKCHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL14299571 0.76 KDM4E (0.39) KCNH2ADKCHRNB2CHRNB4CHRNA3
SCHEMBL30811670 0.75 CHRNB4 (0.40) ADKCCR6CHRNB2CHRNB4CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4582422-A1 METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Global Health Drug Discovery Institute (CN) 2025-07-09 EP disclosed
US-20250214997-A1 METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF GLOBAL HEALTH DRUG DISCOVERY INSTITUTE (CN) 2025-07-03 US disclosed
WO-2024056099-A1 METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 北京华益健康药物研究中心 2024-03-21 WO disclosed
CN-117720533-A MetTL3 inhibitor compound and pharmaceutical composition and application thereof 北京华益健康药物研究中心 2024-03-19 CN disclosed
WO-2023104209-A1 METTL3 INHIBITOR COMPOUND 上海昂阔医药有限公司 2023-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214997-A1 METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF METTL3, METTL14, METTL16 CYP11B1 200/4885CYP11B2 281/4885KCNJ1 4322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.